China's Infant and Toddler Care Products Manufacturer Runben Bio is about to List on SSE
- Chaileedo Press
- Jun 15, 2023
- 3 min read
Runben Bio, the infant and toddler care products manufacturer, updated its prospectus again, announcing its latest financial data. The company’s revenue reached a new high in 2022, hitting 856 million yuan ($119.25 million).
Runben Biotechnology Co., Ltd. (hereinafter referred to as "Runben Bio") has new developments in its IPO on the Shanghai Stock Exchange.
On June 13, Runben Bio updated its prospectus again, announcing its latest financial data. According to the prospectus, Runben Bio's revenue reached a new high in 2022, hitting 856 million yuan ($119.25 million). Among these, the infant and toddler care segment revenue reached 390 million yuan ($54.33 million), accounting for more than 45% of the main business revenue.
Not only that but in 2022, the proportion of infant and toddler care products in the company's revenue exceeded that of mosquito repellent products for the first time, becoming the largest business segment under Runben Bio.
Public information shows that Runben Bio was established in December 2013 with a registered capital of 344 million yuan ($47.92 million). It mainly engages in the research, development, production, and sales of mosquito repellent and personal care products, and has formed three core product lines: mosquito repellent products, infant and toddler care products, and essential oil products.
According to the latest prospectus, from 2020 to 2022, Runben Bio's revenues were 443 million yuan ($61.72 million), 582 million yuan ($81.08 million), and 856 million yuan ($119.25 million), respectively, with net profits of 95 million yuan ($13.23 million), 121 million yuan ($16.86 million), and 160 million yuan ($22.29 million).
By product type, Runben Bio's main business income comes from three major series: mosquito repellent products, infant and toddler care products, and essential oil products. From 2020 to 2022, the company's infant and toddler care product revenues were 144 million yuan ($20.06 million), 217 million yuan ($30.23 million), and 390 million yuan ($54.33 million), accounting for 32.47%, 37.24%, and 45.59% of the main business revenue, respectively.
It is worth mentioning that in 2022, Runben Bio's infant and toddler care product revenue exceeded that of mosquito repellent products for the first time, officially becoming the largest business segment under Runben Bio. It is understood that the company's infant and toddler care products include 14 products such as baby lip balm, comfrey soothing ointment, and baby moisturizing anti-chapping cream, while its mosquito repellent products only have five products such as classic electric mosquito repellent liquid and prallethrin repellent liquid. This suggests that Runben Bio may focus on the infant and toddler care business in the future.
In terms of sales channels, Runben Bio mainly relies on online channels. From 2020 to 2022, the direct contribution of online channels to sales revenue was 78.73%, 77.72%, and 78.04%, respectively. In online channels, Runben Bio mainly focuses on direct sales, with its online direct sales revenue in 2022 reaching 516 million yuan ($71.89 million), accounting for 60.32%.
According to the prospectus, in the first quarter of this year, Runben Bio's reviewed revenue was 152 million yuan ($21.18 million), a year-on-year increase of 49.81%; net profit was 21 million yuan ($2.93 million), a year-on-year increase of over 60%.
In addition, Runben Bio also stated that its revenue for the first half of this year is expected to range from 610 million yuan ($84.98 million) to 630 million yuan ($87.77 million), with a corresponding change compared to the same period last year of 38.96% to 43.51%. Net profit is expected to be between 110 million yuan ($15.32 million) and 120 million yuan ($16.72 million), with a corresponding change compared to the same period last year of 40.04% to 52.77%.
Comments